Stakeholder Perspectives: Innovation within the Biopharma Industry

Stakeholder Perspectives: Innovation within the Biopharma Industry

Regular price $2,495.00 Sale

Published on Feb 19, 2014 - 99 pages

What does innovation mean within the biopharma industry? How much you spend on R&D? How many products you bring to market? How many New Molecular Entities (NME) you have in research?

Within the biopharma industry, R&D output is at odds with R&D investment. Between 1950 and 2010, the number of new molecules (including both biologics and small molecules) brought to market by the biopharma industry, per billion dollars of R&D expenditure, fell by a factor of 100 in inflation adjusted terms. Innovation, it seems, is getting increasingly expensive while the prospect of blockbuster income to pay for it is getting rarer. Something has to change.

So...what are the issues we need to consider?
  • New molecular entity (NME) output is not an accurate reflection of the state of innovation: new ways of measuring innovation within the biopharma industry are needed. Current methods of measuring NME output from either the FDA or EMA provide only a snapshot of what regulatory agencies deem approvable. The industry needs to move beyond NME output as a measure of innovation, taking into account provider, purchaser and user metrics including pipeline activity, clinical success, regulatory approval, patient access, satisfaction of unmet need and overall value to society;
  • Collaboration is critical to success: Industry must leverage the experience, skills and insights from a diverse range of stakeholders such as physicians, patients and payers - this is critical to the future of innovation. But collaboration needs to be smart. Biopharma companies must collaborate only when the expected outcome adds value to society, contributes to better patient outcomes and supports commercial goals;
  • Companies need to be brave: constantly mining a 'comfort zone' of known approaches leads to complacency and limits innovation. While many believe that all of the 'low hanging fruit' have been taken there is another perspective: that there is plenty of fruit left on the tree and companies just need the bravery and vision to look for them.
This FirstView advisory report - the first in a major new series - provides everyone interested in the dynamics of biopharma innovation with a robust understanding of the issues, opinions and insights that are shaping the current environment, and the events that could lead to a change in the future. Every aspect of the report is informed by expert insight gathered from 60-minute interviews with 16 key opinion leaders (KOLs), payers and senior industry executives from leading companies from across Europe and the US.

Experts share their insights on...
  • The impact of innovation within biotechnology over the last 15-20 years
  • A view of what a world without biologics would have looked like
  • The pros and cons of biological therapies
  • Where biologics have been best received and where there is still resistance
  • The role that industry played, and needs to play, within the 'innovation ecosystem'
  • The important and growing roles of key stakeholder groups
  • Attitudes toward innovation within industry
  • New technologies and innovations that are exciting industry at the moment, and hypotheses about the future of innovation and roles in driving it forward
  • This report tackles the pressing innovation issues and questions
What does biopharma innovation mean?
  • Where is innovation coming from?
  • How can the lessons of the last few decades be used to guide future biopharma innovation?
  • What will be the future trends in biopharma innovation?
  • How has biopharma innovation been measured in the past, and do new ways of measuring innovation need to be developed?
  • What must biopharma companies focus on in order to remain competitive and deliver innovation that is truly valued by society?
  • Which companies are currently viewed as being leaders of innovation within the pharmaceutical industry?
  • What disruptive technologies and market dynamics are likely to impact the rate of innovation within the biopharma industry?
  • What do KOLs, payers and industry stakeholders view as critical for biopharma companies to focus on in order to maintain shareholder returns and deliver customer value?
Whether you work in big pharma, a drug discovery company, patient advocacy group or regulatory body, this report Stakeholder Perspectives: Innovation within the Biopharma Industry provides a thought provoking assessment of how we can better cost-effectively develop and bring biopharmaceuticals to the market in a timely manner.

Report Benefits
  • Understand and evaluate the current status of innovation within the biopharma industry, including the key drivers and resistors of innovation
  • Get up to speed with current thinking on how innovation is measured within the biopharma industry
  • Know what potential changes need to be made in terms of how innovation will be assessed in the future
  • Understand clinical, payer and industry opinions of current and future market dynamics
  • Appreciate what the critical opportunities biopharma companies should be investing in and how these opportunities can be realised
Selected Quotes from the Report

'Innovation [within pharma] is a lot like a fine Swiss watch. There are multiple moving parts but if you take one part out, the watch stops. So every part in that watch is absolutely critical to the functioning of that watch in the same way that every key stakeholder group within the innovation ecosystem has a critical role. Whether it be a payer, a physician, a company, a policy maker, a scientist, etc. They all have a role to play and if they stop playing that role, the system falls over.' Former Head of Innovation, Eli Lilly.

'Collaboration is your key for survival for the future. You cannot always count on the old model of finding solutions inside your own company.' Global Head of External Innovation & Strategic Partnerships, Roche.

'If we had a shorter, faster, more efficient regulatory system, then the cost [and time taken] to complete clinical trials would go down. I think we need to re-think how it could be smarter, more efficient. At the moment, the regulatory system is set up to benefit big pharma, not smaller companies.' Scientific Advisor, Innogen Institute.

'My view is that biopharma companies need to be more receptive to new models of innovation, and that includes more collaborations, more discussions, sharing of data. I'm not a big believer of we [the biopharma industry] are better than everyone else and we know better, so I think that being open to the environment is really important.' Head of Innovation at Merck Serono.